Litigation
Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.
settled2:17-cv-06842
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2017-09-06
- Terminated
- 2019-03-30
Patents at issue (1)
Plaintiffs (1)
Defendants (2)
Summary
16-count complaint with the '740 patent among patents-in-suit; motion for judgment on the pleadings on REMS patents denied without prejudice Dec 14, 2018. Later settled March 30, 2019, with Lotus/Alvogen licensed to sell a limited-volume generic after March 2022.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).